CL2017000662A1 - Inhibidores de la histona desmetilasa. - Google Patents

Inhibidores de la histona desmetilasa.

Info

Publication number
CL2017000662A1
CL2017000662A1 CL2017000662A CL2017000662A CL2017000662A1 CL 2017000662 A1 CL2017000662 A1 CL 2017000662A1 CL 2017000662 A CL2017000662 A CL 2017000662A CL 2017000662 A CL2017000662 A CL 2017000662A CL 2017000662 A1 CL2017000662 A1 CL 2017000662A1
Authority
CL
Chile
Prior art keywords
histone demethylase
demethylase inhibitors
inhibitors
histone
pirrolo
Prior art date
Application number
CL2017000662A
Other languages
English (en)
Inventor
Young K Chen
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of CL2017000662A1 publication Critical patent/CL2017000662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

<p>COMPUESTOS DERIVADOS DE PIRROLO[3,2-b]PIRIDINA O SALES DE ELLOS , INHIBIDORES DE HISTONA DESMETILASA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO DEL CANCER.</p>
CL2017000662A 2014-09-17 2017-03-17 Inhibidores de la histona desmetilasa. CL2017000662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051850P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
CL2017000662A1 true CL2017000662A1 (es) 2018-03-23

Family

ID=55533717

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000662A CL2017000662A1 (es) 2014-09-17 2017-03-17 Inhibidores de la histona desmetilasa.

Country Status (17)

Country Link
US (3) US9758517B2 (es)
EP (1) EP3194387B1 (es)
JP (2) JP6723663B2 (es)
KR (1) KR20170048601A (es)
CN (1) CN107001330A (es)
AU (1) AU2015318111A1 (es)
BR (1) BR112017005510A2 (es)
CA (1) CA2961580A1 (es)
CL (1) CL2017000662A1 (es)
CO (1) CO2017003445A2 (es)
EA (1) EA201790604A1 (es)
EC (1) ECSP17022542A (es)
ES (1) ES2751464T3 (es)
IL (1) IL251184A0 (es)
MX (1) MX2017003463A (es)
SG (1) SG11201702119PA (es)
WO (1) WO2016044138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
ES2751464T3 (es) * 2014-09-17 2020-03-31 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018188590A1 (en) * 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CN109709333B (zh) * 2018-08-01 2021-09-24 东南大学 H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2009514893A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MY148893A (en) 2006-12-04 2013-06-14 Novartis Ag Combination of an hdac inhibitor and an antimetabolite
US20100204231A1 (en) 2007-05-04 2010-08-12 Astrazeneca Ab Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
CU24077B1 (es) * 2009-11-10 2015-03-30 Pfizer DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
ES2534804T3 (es) * 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2013028999A1 (en) 2011-08-24 2013-02-28 The Trustees Of Columbia University In The City Of New York Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders
HUE033380T2 (en) * 2012-10-02 2017-11-28 Gilead Sciences Inc Inhibitors of histone demethylases
PL2934145T3 (pl) 2012-12-19 2018-04-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy histonowej
EP2968282B1 (en) * 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
ES2751464T3 (es) * 2014-09-17 2020-03-31 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa

Also Published As

Publication number Publication date
EP3194387A4 (en) 2018-03-07
AU2015318111A1 (en) 2017-04-13
JP6967632B2 (ja) 2021-11-17
ECSP17022542A (es) 2017-05-31
CN107001330A (zh) 2017-08-01
WO2016044138A1 (en) 2016-03-24
US20180271843A1 (en) 2018-09-27
US10231957B2 (en) 2019-03-19
CO2017003445A2 (es) 2017-07-11
JP6723663B2 (ja) 2020-07-15
EA201790604A1 (ru) 2017-09-29
JP2020169183A (ja) 2020-10-15
US9758517B2 (en) 2017-09-12
US20170326116A1 (en) 2017-11-16
EP3194387B1 (en) 2019-07-31
ES2751464T3 (es) 2020-03-31
SG11201702119PA (en) 2017-04-27
US10016401B2 (en) 2018-07-10
BR112017005510A2 (pt) 2018-08-14
IL251184A0 (en) 2017-05-29
MX2017003463A (es) 2017-07-13
KR20170048601A (ko) 2017-05-08
US20160108032A1 (en) 2016-04-21
JP2017529347A (ja) 2017-10-05
CA2961580A1 (en) 2016-03-24
EP3194387A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
CL2016002548A1 (es) Derivados de tubulisina
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
CL2016000925A1 (es) Inhibidores de bromodominio
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
CL2015001437A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CL2017000662A1 (es) Inhibidores de la histona desmetilasa.
EA201691421A1 (ru) Гетероарилы и их применение